Abstract
The authors report a pilot open-label two-center therapeutic trial of oxatomide in
14 steroid-naive DMD boys aged 5–10 years. Comparison of linear evolutions between
3 months medication-free lead-in periods and 6 months treatment periods showed no
significant differences in quantitative (QMT) and manual (MMT) measurements of muscle
strength and timed functional tests. A modest mitigation of strength deterioration
over time cannot be excluded.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Paediatric NeurologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- A role for mast cells in the progression of Duchenne muscular dystrophy? Correlations in dystrophin-deficient humans, dogs, and mice.J Neurol Sci. 1994; 122: 44-56
- Recruitment of mast cells to muscle after mild damage.J Neurol Sci. 1996; 135: 10-17
- Duchenne-like myopathy in double-mutant mdx mice expressing exaggerated mast cell activity.J Neurol Sci. 1995; 131: 1-7
- Dystrophin-deficient myofibers are vulnerable to mast cell granule-induced necrosis.Neuromuscul Disord. 1994; 4: 325-333
- Suppressive effect of oxatomide on the induction of IL2 responsiveness by DF-stimulated lymphocytes from patients with bronchial asthma.Arerugi. 1994; 43: 535-543
- Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology.J Cell Biol. 2000; 151: 1321-1336
- Pre-clinical screening of drugs using the mdx mouse.Neuromuscul Disord. 2000; 10: 235-239
- Clinical evaluator reliability for quantitative and manual muscle testing measures of strength in children.Muscle Nerve. 2001; 24: 787-793
- Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy.Muscle Nerve. 2007; 35: 36-42
- CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy.Ann Neurol. 2005; 58: 151-155
- Linear mixed models for longitudinal data.Springer, New York2000
- Early onset of inflammation and later involvement of TGFβ in Duchenne muscular dystrophy.Neurology. 2005; 65: 826-834
Article info
Publication history
Accepted:
February 15,
2007
Received in revised form:
February 15,
2007
Received:
December 13,
2006
Identification
Copyright
© 2007 European Paediatric Neurology Society. Published by Elsevier Inc. All rights reserved.
